Liver injury induced by sintilimab injection
10.3760/cma.j.cn114015-20220507-00399
- VernacularTitle:信迪利单抗注射液致重度肝损伤
- Author:
Feilang ZHENG
1
Author Information
1. 长治医学院附属和平医院药剂科，长治 046000
- Publication Type:Journal Article
- Keywords:
Immune checkpoint inhibitors;
Chemical and drug induced liver injury;
Sintilimab
- From:
Adverse Drug Reactions Journal
2023;25(2):120-122
- CountryChina
- Language:Chinese
-
Abstract:
A 75-year-old male patient with lung cancer received intravenous infusion of sintilimab 200 mg on day 1, 21 days as one cycle. Three days after the 5th cycles of treatment, the patient developed edema of lower limbs and yellowish skin on whole body. Laboratory tests showed alanine aminotransferase (ALT) 914 U/L, aspartate aminotransferase (AST) 622 U/L, alkaline phosphatase (ALP) 385 U/L, total bilirubin (TBil) 152.6 μmo1/L, direct bilirubin (DBil) 87.9 μmol/L, indirect bilirubin (IBil) 64.7 μmol/L and total bile acid (TBA) 25.8 μmol/L. The liver injury caused by other reasons was excluded by laboratory and auxiliary examination, and it was diagnosed as drug-induced liver injury, which was considered to be related to sintilimab. Drugs such as reduced glutathione, compound glycyrrhizin, ademetionine, polyene phosphatidylcholine, magnesium isoglycyrrhizinate, and ursodeoxycholic acid successively were given. The patient′s edema of lower limbs and yellowish skin gradually subsided. After 25 days of treatments, laboratory tests showed ALT 33 U/L, AST 33 U/L, ALP 92 U/L, TBil 18.2 μmol/L, DBil 5.2 μmol/L, IBil 13.0 μmol/L, and TBA 7.4 μmol/L.
